Intelligencia AI

New York, New York, USA · ≈120 employees · intelligencia.ai

Intelligencia AI is a health technology company that specializes in using Artificial Intelligence (AI) and Machine Learning (ML) to enhance drug development in the pharmaceutical and biotechnology sectors. Founded in November 2017 and headquartered in New York, with additional offices in Athens and Basel, the company aims to de-risk the pharmaceutical industry, which is valued at $1.5 trillion. Intelligencia AI operates as a B2B SaaS provider, offering Data-as-a-Service and AI-as-a-Service solutions, and has raised approximately $12 million to $13.78 million in funding. The company provides a cloud-based platform that helps clients assess and reduce the risks associated with clinical development. Key services include Probability of Technical and Regulatory Success (PTRS) assessments, clinical trial risk estimation, and portfolio strategy optimization. Intelligencia AI serves a diverse clientele, including large pharmaceutical companies, mid-size biotechnology firms, and investors in the biopharmaceutical space. With a team of around 110 professionals, the company is recognized for its rapid growth and is positioned to play a significant role in the future of drug development.